Navigation Links
Arena Submits Response to FDA Complete Response Letter for Lorcaserin
Date:1/3/2012

SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 3, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that Arena has submitted its response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) following review of the lorcaserin New Drug Application (NDA). Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index, or BMI, >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. The companies expect that later this month the FDA will confirm acceptance of the response and assign a new Prescription Drug User Fee Act (PDUFA) date.

"We have worked diligently with Eisai to prepare this submission that we believe will address the issues raised in the complete response letter," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to providing on today's call an overview of the submission contents, including the results of the recently completed rat mechanistic studies, which we believe provide additional data supporting lorcaserin's benefit-risk profile."

Lonnel Coats, President and Chief Executive Officer of Eisai Inc., said, "Weight loss for obese patients and overweight patients with co-morbid conditions remains an area of unmet need. Eisai is pleased to collaborate with Arena in its response to the FDA, an important milestone toward lorcaserin's potential approval."

The response to the lorcaserin CRL includes data and analyses that were not incorporated in the original NDA, including the results of Arena's Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) clinical trial, which evaluated lorcaserin for weight loss in patients with type 2 diabetes. The new
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
2. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
3. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
4. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
6. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
7. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
8. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
10. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
11. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Cynosure, Inc. (NASDAQ: ... for non-invasive and minimally invasive applications, today announced that the ... Officer and Chief Financial Officer Timothy W. Baker ... 53, will continue to serve as CFO and will take ... remains Chairman and Chief Executive Officer. "Tim ...
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... , SALT LAKE CITY, Dec. 16 ... "Company"), a medical device company engaged in the development and ... that Joe Pepper, PhD, has been appointed to the TechniScan ... "Joe has extensive experience running small to large medical devices ...
... EVANSTON, Ill., Dec. 16 Naurex Inc., a new clinical ... disorders based on its novel GFPA NMDA receptor modulators, today ... of its lead compound GLYX-13 and has successfully dosed the ... functional partial agonist (GFPA) selective modulator of the NMDA receptor, ...
Cached Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... fuel cancer as well as evolutionary changes in a ... occur randomly throughout the genome. , However, recent studies ... of multiple mutations that arise simultaneously and in close ... are frequently found in regions where chromosomal rearrangements take ... Cell Reports , may one day lead to new ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is happy ... on July 30th. After months of planning, Dr. Hamilton ... state-of-the-art suite, located only steps away from the original ... one-on-one patient comfort, shorter wait times, and generally a ... new office-suite will continue to provide the same wide ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... OAKLAND, Calif., Aug. 11 The American Heart ... Oakland and,Stanford University Medical Center $3.89 million over ... heart research center that aims to define,optimal clinical ... chronic,heart failure., The Kaiser Permanente Division of ...
... Aug. 11 Perrigo Company,(Nasdaq: PRGO ; ... chewable tablets (famotidine 10 mg; calcium carbonate 800mg;,magnesium ... under their store,brand labels. Perrigo won a successful ... to Pepcid Complete(R) marketed by,Johnson & Johnson - ...
... Inc., a,global leading manufacturer of orthodontic products and ... a full-service,orthodontic laboratory. The O2 Orthodontic Laboratory is ... Carlsbad, CA., "The O2 Orthodontic Laboratory is ... it allows the Company to further its,commitment to ...
... (GICD) and UCSF have identified a key regulatory factor ... the extensive network of arteries, veins, and capillaries that ... research, published in the latest issue of Developmental ... for a wide variety of diseases, such as heart ...
... examinations of PSA screening in younger men, a study published ... of men under age 50 reported undergoing a prostate specific ... year, yet only one in three young black men reported ... , Overall, that,s pretty good news for white men at ...
... chemical might lead to drug treatments for humans , , SUNDAY, ... of mice resistant to diet-induced obesity. , The findings ... in people. They also shed light on the brain circuitry ... energy (i.e., food) an animal takes in and how quickly ...
Cached Medicine News:Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 2Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 3Health News:Kaiser Permanente - Stanford Heart Research Center Funded to Study Treatment Outcomes 4Health News:Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide 2Health News:Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide 3Health News:Ortho Organizers(R) Opens a Full-Service Orthodontic Laboratory 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 3Health News:Study finds more PSA screening awareness needed among high-risk groups 2Health News:Scientists Create Mice Resistant to Obesity 2Health News:Scientists Create Mice Resistant to Obesity 3
... K-ASSAY ASO / RF / ... to be used as a ... concentration for monitoring the performance ... Rheumatoid Factor (RF), and C-Reactive ...
... of benchtop microcentrifuges with the 5424. ... aerosol-tight rotor and a unique, contoured ... ,Model 5424 expands its application range ... microcentrifuge tubes, miniprep spin columns and ...
... hand, the Jarvik 2000 pump is about the ... titanium shell sits a direct-current motor, a rotor ... moving part: a small, spinning titanium impeller that ... 7 liters per minute. Rather than take over ...
... VentrAssist is a new third generation cardiac assist ... heart transplants for patients suffering heart failure., ,It ... left ventricle of the diseased heart to help ... restoring a better quality of life. , ,It ...
Medicine Products: